Drug Approval | April 18, 2022
Amneal achieves second U.S. biosimilars approval with Alymsys
Marks the second of three biosimilars Amneal expects to receive U.S. approval for in 2022
Marks the second of three biosimilars Amneal expects to receive U.S. approval for in 2022
This partnership allows both companies to become first movers to bridge an inevitable gap with the largest organizations in the pharmaceutical, nutraceutical, cosmetic, and veterinary sectors
The company also plans to expand the facility
The association has lined up a string of prominent speakers from the government and private sector. Seasoned veterans and industry bigwigs will grace the two-day event in Mumbai
This product is indicated for the short-term treatment of a breathing problem (apnea) in premature infants
The DRX-Compass helps navigate and accelerate towards superb performance with a solution that grows with its customers
Researchers from the Tel Aviv University successfully engineer the world's first 3D human spinal cord tissue transplant
Mahajan Imaging, which currently has 10 high-end medical diagnostic centres in Delhi-NCR and Jaipur, has ventured into a new field called Integrated Diagnostics
If authorized by the USFDA, the Proof Lab Test System may be used to deliver accurate, actionable, lab-quality results for Covid-19 in as little as 18 minutes
The company plans to file its NDA in China and MAA in the EU in 2022, making Hansizhuang potentially to be the world's first PD-1 inhibitor for the first-line treatment of SCLC
Subscribe To Our Newsletter & Stay Updated
